The leader in pharma sales, Pfizer is well known thanks to several household name drugs, including Lipitor, Advil, Celebrex, Zithromax and the ever-abundant "little blue pill," Viagra. As the company looks at the looming Lipitor patent cliff, CEO Ian Read has been searching for new methods to keep revenue high, other than new approved drugs. Recently, the company has been considering spinning off portions of the company to create smaller, more profitable arms, a polar opposite of former CEO Jeffrey Kindler's bulk-up strategy of years past. The company's past purchases and mergers have included King Pharmaceuticals, Warner-Lambert, SUGEN and a $68 billion purchase, Wyeth, in 2009.

Wyeth provided Pfizer with an influx of 17 new drugs and vaccines, including Enbrel, Effexor, Prevnar and Pristiq, and Pfizer declared the merger made them "one of the most diversified companies in the global health care industry." And the company continues to move forward as it focuses on hot areas, including Alzheimer's, oncology and vaccines.

The company's legal woes have caused headaches as well. Pfizer has paid over $340 million in settlements for its menopause treatment, Prempro and has 1,200 cases pending for the anti-smoking drug Chantix. Back in 2009, it paid $1.3 billion for illegal marketing fines for the painkiller Bextra, making it the largest fine in United States history.

Pfizer has stayed in the top two on FiercePharma's annual layoffs list for the past three years, thanks in part to the company's 2009 megamerger with Wyeth, and the pressure could be felt for another five years. The company also placed second in the Top 15 R&D Budgets, with $7.4 billion in 2009. But those numbers will continue to slip as Pfizer looks towards development deals instead of in-house research.



Latest Headlines

Latest Headlines

To buy Wyeth, Pfizer may need to sell

Don't tell Rover, but Pfizer may have to sell off some of its animal-health business to get the government to OK its buyout of Wyeth. At Cowen & Co.'s investor conference yesterday, CFO Frank

Pfizer nabs $13.5B in U.S. bond issue

No one can accuse Pfizer leadership of timidity. With the nation mired in a deep recession, the company Tuesday launched the second largest U.S.-dollar bond issue in history, a $13.5 billion offering

Will Wyeth buyout derail Pfizer's R&D makeover?

Pfizer's plans to adopt a lean, mean biotech approach to R&D gets a cautious thumbs up from Frank Lichtenberg, a Courtney Brown professor of business at Columbia Business School. In a case study

Pfizer preps for major bond deal

These days, drugmakers are heroes--in the financial markets. All the M&A activity in the pharma sector is certainly funding many an investment banker's paycheck. And every pharma company that

Pfizer chief's pay leaps 17% to $14.8M

It's good to be Jeff Kindler (photo) these days. The Pfizer CEO recently bagged the biggest pharma deal around, with his $68 billion acquisition of Wyeth. The analysts who were agitating for him to

Pfizer's Sutent strategy pays off

Sutent performs for Pfizer strategy-wise--and in a newly released trial. First, the strategy--let's call it Never Give In, Never Never. To persuade the U.K.'s National Institute for Clinical

Drugmakers feel impact of preemption ruling

Previously rejected by the U.S. Court of Appeals for the Third Circuit in Philadelphia, lawsuits against GlaxoSmithKline and Pfizer were revived this week. Brought by relatives of patients who

MannKind buys Pfizer insulin plant for $33M

Inhalable indulin company MannKind has agreed to purchase Pfizer's Frankfurt-based insulin facility, including the relevant real property rights, the production equipment, a quantity of bulk insulin

Rumor: Pfizer, Sanofi vie for Wockhardt biotech

Rumor: Pfizer and Sanofi-Aventis are reportedly vying to buy the biotech business built up by India's Wockhardt, the country's sixth largest drugmaker. Analysts say the buyout may require Wockhardt

Covalent vaccination method offers instant protection

A team of researchers led by Scripps Professor Carlos Barbas, III, Ph.D., report a new method of vaccination can provide instant protection against a pathogen. Testing the concept in mice, scientists